Mark Cuban’s Cost Plus Drugs launched in January 2022 with a proposition simple enough to be disruptive: sell generic drugs at the manufacturer’s cost plus a fifteen-percent markup, a dispensing fee, and a shipping cost, with no PBM, no formulary negotiation, and no rebate. The prices it published for common generics were, in many cases, ninety percent below what the same drugs cost under standard PBM arrangements. For individual patients, particularly those without insurance coverage for the relevant drug, this was transformative. For the healthcare policy community, it was a useful demonstration that the ambient pricing in the generic drug market had for years contained extraordinary margin that the incumbent system had quietly retained.
What Cost Plus Proved and What It Did Not
The demonstration value of Cost Plus Drugs is significant and should not be dismissed. It established, with market evidence rather than theoretical argument, that the spread between the cost of producing and distributing common generics and the price at which they are dispensed under commercial insurance arrangements is substantial — in some cases representing multiples of the actual acquisition cost. That spread benefits PBMs, wholesalers, and in some cases pharmacies, with limited transmission to either plan sponsors or patients. The Cost Plus model compresses that spread to near zero, and the resulting prices are credible because they are based on disclosed cost structures rather than negotiated discounts off list prices whose basis is obscure.
What Cost Plus has not demonstrated is the ability to address the specialty drug cost problem that dominates employer pharmacy spend. The platform’s formulary is predominantly generic, with limited specialty drug offerings — a constraint driven by the complexity of specialty drug distribution, the cold chain and clinical support requirements of biologics, and the manufacturer contracting dynamics that make specialty drug pricing resistant to the transparent cost-plus model that works for simple generics. Generic drugs account for roughly ninety percent of prescription volume but only twenty to thirty percent of pharmacy spend. The Cost Plus model, even at full penetration, does not address the seventy to eighty percent of pharmacy expenditure that drives employer cost management anxiety.
The Employer Adoption Challenge
Several large self-insured employers have incorporated Cost Plus Drugs into their pharmacy benefit design — most commonly as a complementary channel available to employees for certain generic drugs, alongside the primary PBM relationship. The integration typically works through a direct-to-member benefit that allows employees to purchase specified generics through Cost Plus and receive reimbursement from the employer plan. This is operationally workable but requires employee activation — employees must be aware of the benefit, comfortable with a new purchasing channel, and motivated to use it for appropriate drugs. Activation rates for alternative pharmacy channels have historically been lower than employers expect, driven by habit, physician prescription routing, and the behavioral inertia that characterizes medication management.
The incumbent PBM response to Cost Plus Drugs has been instructive. Rather than dramatically repricing generic drugs to compete on the Cost Plus model, major PBMs have largely maintained their existing contracting structures while accelerating investment in generic drug cost-reduction programs — preferred generic networks, mail-order programs, and specialty carve-out arrangements — that do not require the fundamental restructuring of their revenue model that the Cost Plus model implies. This is rational incumbent behavior: the PBM captures value through the complexity of its existing arrangements, and simplifying the model to compete with a transparent cost-plus approach would cannibalize revenue that the incumbent currently retains. The market disruption that Cost Plus represents may be most consequential not in its direct market share but in the normative pressure it creates for transparency in a market that has historically resisted it.
The Scalability Question
The most honest assessment of Cost Plus Drugs is that it has accomplished something meaningful — demonstrating that generic drug pricing contains structural excess — without resolving the problem it identified. Scaling the model requires manufacturer cooperation, pharmacy network agreements, and plan sponsor integration that create friction the original proposition’s simplicity obscured. The specialty drug gap means that even a fully scaled Cost Plus deployment addresses a minority of employer pharmacy expenditure. And the behavioral economics of employee drug purchasing — habit, physician influence, formulary defaults — mean that making a cheaper channel available is not the same as making it used. Cost Plus Drugs is a genuinely useful innovation that has moved the conversation. Whether it eventually moves the market is still being written.
